Our recent activity

ONA Therapeutics Appoints Dr Michel Detheux as Independent Chair to Board of Directors

  • Seasoned biotech executive with a wealth of experience and a track-record of strategic alliances in the immuno-oncology space

ONA Therapeutics (“ONA”), which is focused on the discovery and development of therapeutic biologics targeting lipid metabolism to treat advanced cancer, today announces the appointment of Dr Michel Detheux as Independent Chair to its Board of Directors.

Dr Michel Detheux is a veteran biotech executive with 25 years’ experience within the industry. He is currently the President and CEO of iTeos Therapeutics (NASDAQ:ITOS), a clinical stage, publicly-traded biotech company developing novel immuno-oncology therapies focused on key mechanisms of immunosuppression. Dr Detheux has spearheaded several capital raises and transactions for iTeos, including an initial public offering on Nasdaq and strategic collaborations with Pfizer and GlaxoSmithKline.

Dr Detheux studied at the Université Catholique de Louvain, receiving his undergraduate degree and his PhD in biochemistry, before completing his post-doc at the University of Glasgow. Dr Detheux also holds a business certificate from Solvay Business School.

Valerie Vanhooren, Chief Executive Officer and Co-Founder of ONA Therapeutics said: “We are thrilled to welcome Dr Michel Detheux as Independent Chair to the Board of Directors. Dr Detheux’s expertise and outstanding track record will be invaluable to ONA as we advance our preclinical pipeline of novel therapies addressing the unmet medical need of patients with advanced cancer.”

Dr Michel Detheux, Chair of ONA Therapeutics, said: “I am delighted to be joining ONA Therapeutics at this stage of the company’s growth and progression. ONA has a unique combination of novel science, good investor base and bright talents to develop highly innovative therapeutics.”

Internal
September 15, 2022

Asabys launches a new €200m fund to invest in biotech & healthtech

READ THIS NEWS IN SPANISH The fund’s first closing is expected by the end of this year, with commitments from institutional and private investors such as Banc Sabadell and the…
Portfolio
September 13, 2022

Agomab Therapeutics Selected as One of Fierce Biotech’s “Fierce 15” Companies of 2022

Agomab Therapeutics NV (‘Agomab’) today announced that Fierce Biotech has named the company as one of 2022’s Fierce 15 biotechnology companies, designating it as one of the most promising early-stage…
Portfolio
July 13, 2022

Agomab Raises Additional $40.5 Million Through Series B Extension Bringing Total Amount to $114M

READ THIS NEWS IN SPANISH ● Extension led by Pfizer with participation from new investors Walleye Capital and Asabys Partners as well as existing investors ● Funding will support next…